European Medicines Agency accepts tofersen MAA to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis
Biogen Inc.announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for review of tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-ALS is a progressive and uniformly fatal disease that affects less than 1,000 people in Europe
There is currently no treatment targeted for SOD1-ALS.
“Through our clinical development program, we have seen that tofersen has the potential to slow the progression of this relentless and ultimately fatal disease,” said Priya Singhal, M.D., M.P.H., Head of Global Safety and Regulatory Sciences and Interim Head of R&D at Biogen. “Regulatory submissions in the U.S. and now EU represent an important step in our efforts to bring the first genetically-targeted treatment for SOD1-ALS to the ALS community as quickly as possible.”
The MAA includes results from the Phase III VALOR study, its open label extension (OLE) study, a Phase 1 study in healthy volunteers and a Phase 1/II study evaluating ascending dose levels. Also included are the most current 12-month integrated results from VALOR and the OLE study that were recently published in The New England Journal of Medicine.
Tofersen is also under review with the FDA with Priority Review and has a Prescription Drug User Fee Act action date of April 25, 2023.
"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS"- Timothy M. Miller, M.D., Ph.D., Merit E. Cudkowicz, M.D., Angela Genge, M.D., Pamela J. Shaw, M.B., B.S., M.D., Gen Sobue, M.D., Ph.D., et al., for the VALOR and OLE Working Group.
Related news and insights
GSK plc announced that the FDA has approved Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. Jesduvroq is the first innovative medicine for anaemia treatment in over 30 years and the only HIF-PHI approved in the US, providing a new oral, convenient option for patients in the US with anaemia of CKD on dialysis.
Biophytis SA a clinical- stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, released the final results from its phase II-III COVA clinical study evaluating Sarconeos (BIO 101) in the treatment of COVID-19-related respiratory failure.